Serum sBCMA in primary and secondary antibody deficiency
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxaf065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Danai Bagkou Dimakou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham,…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, B-Cell Maturation Antigen, Agammaglobulinemia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United Kingdom Research and Innovation.
Abstract (Originalsprache)
B-cell maturation antigen (BCMA) is a B cell surface receptor that regulates B cell activation, proliferation and survival. BCMA can be cleaved from the cell surface, producing soluble BCMA (sBCMA), which has been studied as a disease biomarker in systemic lupus erythematosus, multiple sclerosis and multiple myeloma. Reduced sBCMA concentrations have been associated with the severity of different primary antibody deficiencies. We explored the relationship between sBCMA concentrations, humoral immune responses to SARS-CoV-2 vaccination and disease complications in 107 individuals with primary (PAD) and secondary antibody deficiency (SAD) enrolled in the COVID-19 in Antibody Deficiency (COV-AD) study. Serum sBCMA concentrations were significantly reduced in PAD compared to healthy controls and asymptomatic selective IgA deficiency. Individuals with X- linked agammaglobulinemia and common variable immunodeficiency (CVID) demonstrated the lowest serum concentrations of sBCMA. sBCMA concentrations in SAD were highly variable. Amongst individuals with CVID, peripheral blood CD19 count, but not sBCMA concentrations discriminated SARS-CoV-2 vaccine responders. sBCMA was significantly lower in individuals with CVID and bronchiectasis and outperformed serum IgA and IgM concentrations in discriminating this subgroup. sBCMA was not associated with any other complication of CVID. Our data highlights the potential of sBCMA as biomarker to support the assessment of antibody deficiency. In PAD, sBCMA may contribute to the risk stratification of disease severity and identify those at risk of bronchiectasis. In SAD, it may identify subgroups that would benefit from intensive monitoring and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
- Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Institute of Immunity and Transplantation, University College London, London, UK.
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.
ORCID-Profile: Nicholas E Peters, Adrian M Shields
Förderung
- United Kingdom Research and Innovation
Zitieren
APA
Bagkou Dimakou, D., Peters, N. E., Burns, S. O., Richter, A. G., & Shields, A. M. (2025). Serum sBCMA in primary and secondary antibody deficiency. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf065
Vancouver
Bagkou Dimakou D, Peters NE, Burns SO, Richter AG, Shields AM. Serum sBCMA in primary and secondary antibody deficiency. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf065
BibTeX
@article{BagkouDimakou2025,
author = {Bagkou Dimakou, Danai and Peters, Nicholas E and Burns, Siobhan O and Richter, Alex G and Shields, Adrian M},
title = {Serum sBCMA in primary and secondary antibody deficiency},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxaf065}
}
EUVIMED